Last Update 21 Jul 26
Fair value Increased 20%HCAT: Cost Cuts And Cleaner Quarters Will Guide A Cautious Reset
Health Catalyst's analyst price targets have moved higher, with recent updates pointing to a range of around $1.75 to $3 as analysts factor in a lower discount rate, slightly less revenue decline, and expectations for cleaner quarters ahead.
Analyst Commentary
Recent Street research on Health Catalyst highlights a mix of optimism around the updated models and caution around execution risks into upcoming quarters.
Bullish Takeaways
- Bullish analysts have raised price targets into a US$1.75 to US$3 range, suggesting updated models that reflect current expectations on revenue trends and capital structure.
- Some models account for the pending Vitalware sale, which analysts view as an important input for refining valuation and balance sheet assumptions.
- Expectations for cleaner quarters ahead are seen as a potential support for the stock if reported results line up closely with these refreshed forecasts.
- Sector recovery from earlier in the year is factored into certain models, which analysts see as relevant context when comparing Health Catalyst to peers on growth and execution.
Bearish Takeaways
- Bearish analysts are focused on the risk that expectations may already be high heading into earnings, which could limit upside if Health Catalyst delivers only in line results.
- There is sensitivity to any indication of revenue decline that is worse than modeled, which could put pressure on valuation if growth expectations need to be revised.
- Some research points to previous price target reductions, signaling concern around execution consistency and the need for evidence of steadier delivery.
- Analysts looking more cautiously at the stock highlight that a cleaner quarter may be required just to maintain current price levels, rather than to drive a rerating higher.
What’s in the News for Health Catalyst
- Health Catalyst did not approve a proposal to restate its Amended and Restated Certificate of Incorporation that would have phased out the classified board structure and moved to annual director elections starting with the 2029 annual meeting. This decision keeps the current staggered board framework in place for now. (Source: Changes in Company Bylaws/Rules)
- Health Catalyst was dropped from multiple FTSE Russell indexes, including the Russell 3000E, Russell 3000, Russell 3000 Value Benchmark, Russell 3000E Value Benchmark, Russell 2500, Russell 2500 Value Benchmark, Russell 2000, Russell 2000 Value Benchmark, Russell 2000 Dynamic Index, and Russell Small Cap Completeness and Small Cap Comp Value Benchmarks. (Source: Index Constituent Drops)
- Health Catalyst recorded goodwill impairment charges of US$95,501,000 for the first quarter ended March 31, 2026. (Source: Impairments/Write Offs)
- Health Catalyst provided earnings guidance, with total revenue expected at US$68 million to US$70 million for the second quarter of 2026 and US$260 million to US$265 million for full year 2026. (Source: Corporate Guidance)
- As part of Project Nexus, Health Catalyst authorized a workforce reduction of about 9% and plans to eliminate roughly 100 additional open, budgeted roles across the US and India, with the goal of achieving a meaningful reduction in its cost structure. (Source: Discontinued Operations/Downsizings)
Valuation Changes for Health Catalyst
- Fair Value: The updated fair value estimate increased from $1.75 to $2.10, a rise of about 20%.
- Discount Rate: The discount rate used in the model shifted from 11.17% to 10.54%, a modest reduction of roughly 0.63 percentage points.
- Revenue Growth: The expected revenue decline eased from 9.44% to 8.95%, indicating a slightly smaller contraction is now modeled.
- Net Profit Margin: The net profit margin assumption remains effectively unchanged at around 6.69%.
- Future P/E: The forward P/E multiple increased from 13.61x to 15.80x, indicating a higher earnings multiple in the updated valuation work.
4 viewsusers have viewed this narrative update
Key Takeaways
- Expansion of AI-driven solutions and proprietary data assets, along with industry trends, will drive margin growth, premium pricing, and sustained revenue gains.
- Platform migration and cost restructuring set the stage for improved profitability, operating leverage, and consistent technology segment growth.
- Health Catalyst faces ongoing revenue pressure from client spending cuts, strategic downsizing, and macroeconomic headwinds, with uncertain prospects for sustained growth and profitability.
Catalysts
About Health Catalyst- Provides data and analytics technology and services to healthcare organizations in the United States.
- The company's focus on expanding its high-margin applications portfolio, driven by ongoing client cross-sell momentum and strong adoption of modular AI-enabled solutions, is positioned to accelerate gross margin expansion and adjusted EBITDA growth as macro headwinds stabilize (positively impacting margins and earnings).
- Migration of platform clients to the new Ignite infrastructure is expected to largely complete by mid-2026, at which point the current revenue headwinds from clients "pocketing" migration cost savings will subside-setting the stage for renewed and more consistent Technology segment growth (positively impacting revenue trajectory).
- Secular industry drivers-including the shift to value-based care and the demand for advanced data analytics to meet regulatory and efficiency goals-are expected to support ongoing demand for Health Catalyst's core offerings, expanding its addressable market and sustaining longer-term revenue growth.
- Management's proactive cost restructuring, contract repricing, and organizational streamlining are on track to deliver $40 million in annualized profitability improvements, enabling sustainable operating leverage and improvements in net margin and free cash flow-well ahead of earlier targets.
- The company's substantial investment in proprietary data assets, AI/ML-driven analytics, and its ability to leverage deep integration with over 1,100 healthcare clients position it to command premium pricing, foster high retention, and benefit disproportionately as digitization and AI adoption accelerate across the healthcare sector (driving both revenue and margin expansion).
Health Catalyst Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Health Catalyst's revenue will decrease by 9.0% annually over the next 3 years.
- Analysts are not forecasting that Health Catalyst will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Health Catalyst's profit margin will increase from -87.7% to the average US Healthcare Services industry of 6.7% in 3 years.
- If Health Catalyst's profit margin were to converge on the industry average, you could expect earnings to reach $15.3 million (and earnings per share of $0.18) by about July 2029, up from -$265.3 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 15.9x on those 2029 earnings, up from -0.6x today. This future PE is lower than the current PE for the US Healthcare Services industry at 33.8x.
- Analysts expect the number of shares outstanding to grow by 5.0% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 10.54%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Significant and accelerated Medicaid and research funding cuts are causing widespread financial strain and uncertainty among Health Catalyst's core end markets-especially not-for-profit and academic medical center clients-which is leading to lower client spending, smaller extension contracts, and delayed bookings, directly impacting both near
- and long-term revenue growth.
- A pronounced trend of existing clients "pocketing" cost savings from Ignite platform migrations, rather than reinvesting these savings in expansion or new offerings, is compressing dollar-based net retention to the low 90s and creating persistent top-line headwinds that are expected to last at least through mid-2026.
- The company's Professional Services segment faces strategic downsizing, including the exit of lower-margin or unprofitable contracts and workforce reductions impacting 9% of employees, resulting in immediate declines in Services revenue in 2025 and 2026, and introducing risk of weakened client support and scalability, negatively affecting both revenue and operating consistency.
- Persistent macroeconomic pressures, such as inflation and potential expiration of premium subsidies, combined with industry conservatism and risk aversion, are causing health systems to defer or shrink technology spending, limiting the pace of Health Catalyst's pipeline conversion and new client acquisition and thus dampening revenue growth prospects for 2026 and possibly 2027.
- The company's removal of ambitious 2028 revenue and EBITDA targets, stated cessation of near
- to mid-term M&A activity, and reliance on maintaining profitability through restructuring rather than organic top-line growth, collectively raise concerns about Health Catalyst's ability to reignite sustainable revenue expansion-a risk that could constrain future earnings momentum and share price appreciation.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $2.1 for Health Catalyst based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $3.0, and the most bearish reporting a price target of just $1.75.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $228.3 million, earnings will come to $15.3 million, and it would be trading on a PE ratio of 15.9x, assuming you use a discount rate of 10.5%.
- Given the current share price of $2.1, the analyst price target of $2.1 is 0.0% different. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Health Catalyst?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
US$1.75
FV
18.9% overvalued intrinsic discount14
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$2
FV
4.0% overvalued intrinsic discount32
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative